Leerink Partners: 'MIRM’s Bluejay Deal Nice External Recognition of HDV Value; Positive for VIR'
Tweet Send to a Friend
Leerink Partners analyst Roanna Ruiz reiterated an Outperform rating and $16.00 price target on Vir Biotechnology (NASDAQ: VIR)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
